Nestlé To Buy Peanut-Allergy Pharma Company
The food giant is buying a California biopharmaceutical company in a deal that values the startup at $2.6 billion.
The Wall Street Journal:
Nestlé Moves Further Into Health, Buying Peanut-Allergy Treatment Maker
Nestlé SA said it agreed to buy Aimmune Therapeutics Inc., a biopharmaceutical company that earlier this year won approval for the first treatment for peanut allergies, in a deal valuing the company at $2.6 billion, including debt. Nestlé previously had a large stake in Brisbane, Calif.-based Aimmune. The agreement to buy the rest of the company bulks up the Switzerland-based packaged-food giant’s decades-old health-science unit. It also adds a potential blockbuster prescription medication to its portfolio, amid a three-year shake-up at the maker of Nespresso coffee and Purina pet food engineered by Chief Executive Mark Schneider, a former health-care executive. (Bugault, 8/31)
In other health industry news —
Reuters:
New Zealand's Abano Healthcare Enters $80 Million Buyout Deal With Consortium
Abano Healthcare Group Ltd said on Monday it entered a revised buyout deal with a consortium, after the initial offer was dropped due to deterioration in the medical services provider’s business because of the coronavirus pandemic. (8/30)
AP:
No Action From Pritzker's COVID-19 Price-Gouging Pursuit
The coronavirus pandemic had steamrolled Illinois, and amid the helter-skelter of counting hospital beds, keeping pace with ever-changing federal health guidance and maneuvering a market-turned-minefield of protective-gear prices, Gov. J.B. Pritzker made a pledge.“Price-gouging will not be tolerated,” the Democrat declared in March, later promising that instances of unfair pricing would be brought to the attention of Attorney General Kwame Raoul. (O'Connor, 8/30)
